Pancreatic islet xenotransplantation: The potential for tolerance induction

Immunology Today

Volumn 21, Issue 1, 2000, Pages 42-48

  Smith, Richard M ^a   Mandel, Tom E ^b  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GLUCOSE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; INTERLEUKIN 5; LYMPHOTOXIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN PRESENTING CELL; CONTROLLED STUDY; GENETIC ENGINEERING; GLUCOSE METABOLISM; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PANCREAS ISLET; PRIORITY JOURNAL; REVIEW; SWINE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; HUMANS; IMMUNE TOLERANCE; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MODELS, IMMUNOLOGICAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034046938     PISSN: 01675699     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5699(99)01554-6     Document Type: Review

References (61)

1. Bowen K.M., Lafferty K.J. Reversal of diabetes by allogenic islet transplantation without immunosuppression. Aust. J. Exp. Biol. Med. Sci. 58:1980;441-447.
2. Collier S.A., Mandel T.E. Reduction of the immunogenicity of fetal mouse pancreas allografts by organ culture in 90 percent oxygen. Transplantation. 36:1983;233-237.
3. Ballinger W.F., Lacy P.E. Transplantation of intact pancreatic islets in rats. Surgery. 72:1972;175-186.
4. Kendall D.M., Robertson R.P. Pancreas and islet transplantation: challenges for the twenty-first century. Endocrinol. Metab. Clin. North Am. 26:1997;611-630.
5. Kenyon N.S.et al. Islet cell transplantation: beyond the paradigms. Diabetes Metab. Rev. 12:1996;361-372.
6. Alejandro R.et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes. 46:1997;1983-1989.
7. Scharp D.W.et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation. 51:1991;76-85.
8. Mandel T.E.et al. Fetal pancreal transplantation in non-obese diabetic (NOD) mice. A comparison of iso-, allo- and xenografts. Horm. Metab. Res. 5(Suppl.):1990;166-173.
9. Hamelmann W.et al. Immediate destruction of xenogeneic islets in a primate model. Transplantation. 58:1994;1109-1114.
10. Mandel T.E.et al. A comparison of organ cultured fetal pancreas allo-, iso-, and xenografts (pig) in non-immunosuppressed non-obese diabetic mice. Am. J. Pathol. 147:1995;834-844.
11. Mandel T.E.et al. Transplantation of normal and DAF-transgenic fetal pig pancreas into cynomolgus monkeys. Transplant. Proc. 29:1997;940.
12. Mandel T.E. Fetal islet xenotransplantation in rodents and primates. J. Mol. Med. 77:1999;155-160.
13. Stock P.G.et al. The alloimmune response against pancreatic islets is generated by both direct and indirect pathways. Transplant. Proc. 23:1991;819-820.
14. Parr E.L.et al. Cellular changes in cultured mouse thyroid glands and islets of Langerhans. Transplantation. 30:1980;135-141.
15. Bretzel R.G.et al. Impact of culture and cryopreservation on MHC class II antigen expression in canine and porcine islets. Horm. Metab. Res. 25(Suppl.):1990;128-132.
16. Smith D.K.et al. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent β cell destruction in diabetic NOD mice. Transplantation. 64:1997;1040-1049.
17. + macrophage and not a T-lymphocyte. Transplantation. 60:1995;594-601.
18. Krieger N.R.et al. Rat pancreatic islet and skin xenograft survival in CD4 and CD8 knockout mice. J. Autoimmun. 10:1997;309-315.
19. Karlsson-Parra A.et al. Xenograft rejection of porcine islet-like cell clusters in normal and natural killer cell-depleted mice. Transplantation. 61:1996;1313-1320.
20. Kovarik J.et al. Expression of both Th1 and Th2 cytokines correlates with the histological rejection of MHC-matched and MHC-mismatched fetal pancreas allografts in mice. Immunol. Cell Biol. 75:1997;303-309.
21. Auchincloss H.J., Sachs D.H. Xenogeneic transplantation. Annu. Rev. Immunol. 16:1998;433-470.
22. Lacy P.E.et al. Prolongation of islet xenograft survival without continuous immunosuppression. Science. 209:1980;283-285.
23. Lenschow D.J.et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science. 257:1992;789-792.
24. Faustman D., Coe C. Prevention of xenograft rejection by masking donor HLA class I antigens. Science. 252:1991;1700-1702.
25. + T cell-depleted mice. Transplantation. 49:1990;849-856.
26. Zhao Y.et al. Skin graft tolerance across a discordant xenogeneic barrier. Nat. Med. 2:1996;1211-1216.
27. Field E.H.et al. Balancing the immune system for tolerance. A case for regulatory CD4 cells. Transplantation. 64:1997;1-7.
28. Waldmann H., Cobbold S. How do monoclonal antibodies induce tolerance? A role for infectious tolerance? Annu. Rev. Immunol. 16:1998;619-644.
29. Dallman M.J. Cytokines and transplantation: Th1/Th2 regulation of the immune response to solid organ transplants in the adult. Curr. Opin. Immunol. 7:1995;632-638.
30. Wren S.M.et al. Evidence for early Th 2 T cell predominance in xenoreactivity. Transplantation. 56:1993;905-911.
31. Nikolic B., Sykes M. Bone marrow chimerism and transplantation tolerance. Curr. Opin. Immunol. 9:1997;634-640.
32. Jenkins M.K.et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cell. J. Immunol. 147:1991;2461-2466.
33. Schwartz R.H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 71:1992;1065-1068.
34. Finck B.K.et al. Treatment of murine lupus with CTLA4Ig. Science. 265:1994;1225-1227.
35. Kuchroo V.K.et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
36. Pearson T.C.et al. Transplantation tolerance induced by CTLA4-Ig. Transplantation. 57:1994;1701-1706.
37. Lenschow D.J.et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1995;1145-1155.
38. Lenschow D.J.et al. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation. 60:1995;1171-1178.
39. Sayegh M.H., Turka L.A. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J. Am. Soc. Nephrol. 6:1995;1143-1150.
40. Sayegh M.H.et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 181:1995;1869-1874.
41. Goldrath A.W.et al. Retention of endocrine function in the scid-Hu pancreas mouse - a model for the development of human fetal islet tissue. Transplantation. 59:1995;1497-1500.
42. Roncarolo M.G.et al. Human T- and B-cell functions in SCID-hu mice. Semin. Immunol. 8:1996;207-213.
43. Marcus H.et al. Allograft and xenograft rejection in C3H/SCID mice: a new model for the study of non-T cell graft rejection mechanisms. Transplantation. 61:1996;777-783.
44. Sawada T.et al. Human cell-mediated rejection of porcine xenografts in an immunodeficient mouse model. Transplantation. 63:1997;1331-1338.
45. Moses R.D.et al. Evidence that multiple defects in cell-surface molecule interactions across species differences are responsible for diminished xenogeneic T cell responses. Transplantation. 53:1992;203-209.
46. Lucas P.J.et al. The human antimurine xenogeneic cytotoxic response I. Dependence on responder antigen-presenting cells. J. Immunol. 144:1990;4548-4554.
47. Yamada K.et al. Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leucocyte reaction and for both direct and indirect pathways of recognition. J. Immunol. 115:1995;5249-5256.
48. Shiroki R.et al. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice: a model for human islet allograft rejection. Transplantation. 57:1994;1555-1562.
49. Shiroki R.et al. Human peripheral blood leukocyte-reconstituted severe combined immunodeficient mouse: analysis of the human immune response against porcine islet transplantation. Transplantation. 63:1997;818-823.
50. Rouleau M.et al. Antigen-specific cytotoxic T cells mediate human fetal pancreas allograft rejection in SCID-hu mice. J. Immunol. 157:1996;5710-5720.
51. MacKenzie D.A.et al. Acute graft rejection of human fetal pancreas allografts using donor-specific human peripheral blood lymphocytes in the SCID mouse. Transplantation. 61:1996;1461-1464.
52. Tzakis A.G.et al. Early tolerance in pediatric liver allograft recipients. J. Pediatr. Surg. 29:1994;754-756.
53. Burlingham W.J. Chimerism after organ transplantation: is there any clinical significance? Clin. Transplant. 10:1996;110-117.
54. Kimikawa M.et al. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation. 64:1997;709-716.
55. Greenstein J.L., Sachs D.H. The use of tolerance for transplantation across xenogeneic barriers. Nat. Biotechnol. 15:1997;235-238.
56. Sablinski T.et al. Pig to monkey bone marrow and kidney xenotransplantation. Surgery. 121:1997;381-391.
57. Naji A. Induction of tolerance by intrathymic inoculation of alloantigen. Curr. Opin. Immunol. 8:1996;704-709.
58. + donor marrow cells. Cell. Immunol. 181:1997;127-138.
59. Groth C.G.et al. Transplantation of porcine fetal pancreas to diabetic patients. Lancet. 344:1994;1402-1404.
60. Paradis K.et al. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science. 285:1999;1236-1241.
61. Patience C.et al. Infection of human cells by an endogenous retrovirus of pigs. Nat. Med. 3:1997;282-286.